Micca Joseph L, Galvin James E, Velting Drew M, Meng Xiangyi
Private Practice, Marietta, GA, USA.
Alzheimer Disease Center, Departments of Neurology and Psychiatry, New York University Langone Medical Center, New York, NY, USA.
SAGE Open Med. 2014 Dec 1;2:2050312114561569. doi: 10.1177/2050312114561569. eCollection 2014.
Investigate efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease on Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items and domains.
Retrospective analysis of the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study, using factor analysis to establish "best fit" for Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items into domains. Treatment differences (13.3 vs 4.6 mg/24 h patch) on items and domains were assessed.
Overall, 632 patients provided Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version data. Factor analysis yielded four domains. The 13.3 versus 4.6 mg/24 h patch demonstrated significantly greater efficacy on "Daily function" (p = 0.038), supported by greatest effect sizes on items within this domain, and trend toward greater efficacy on "Communication" (p = 0.052). No significant between-group differences were observed on "Independence" (p = 0.600) or "Environment" (p = 0.261).
The 13.3 mg/24 h patch was superior to 4.6 mg/24 h patch on "Daily function" in severe Alzheimer's disease.
研究13.3毫克/24小时卡巴拉汀贴片对重度阿尔茨海默病患者在阿尔茨海默病协作研究日常生活量表 - 严重损害版项目和领域方面的疗效。
对为期24周的随机双盲日常生活与认知（ACTION）研究进行回顾性分析，采用因子分析将阿尔茨海默病协作研究日常生活量表 - 严重损害版项目“最佳拟合”为各个领域。评估项目和领域上的治疗差异（13.3毫克/24小时贴片与4.6毫克/24小时贴片）。
总体而言，632名患者提供了阿尔茨海默病协作研究日常生活量表 - 严重损害版数据。因子分析得出四个领域。13.3毫克/24小时贴片与4.6毫克/24小时贴片相比，在“日常功能”方面显示出显著更高的疗效（p = 0.038），该领域内各项目的效应量最大，且在“沟通”方面有更高疗效的趋势（p = 0.052）。在“独立性”（p = 0.600）或“环境”（p = 0.261）方面未观察到显著的组间差异。
在重度阿尔茨海默病中，13.3毫克/24小时贴片在“日常功能”方面优于4.6毫克/24小时贴片。
